Advanced BioDesign

Advanced BioDesign is honored to be featured in Le Figaro Économie, which highlights our cutting-edge approach to overcoming cancer resistance through targeted inhibition of ALDH1—a key enzyme that enables tumor survival and relapse.

Our lead compound, ABD-3001, currently in Phase 1 clinical trials for acute myeloid leukemia (AML), has shown promising biological activity even at low doses. Patients have experienced rapid hematological improvements and sustained recovery, reinforcing the therapeutic potential of our strategy.

Beyond AML, a recent compassionate use case in relapsed T-cell acute lymphoblastic leukemia (T-ALL) demonstrated disease stabilization and excellent tolerance, opening the door to broader applications in aggressive hematologic malignancies.

To accelerate clinical development and expand access to our therapy, Advanced BioDesign is actively seeking strategic funding partners. Our goal is to initiate combination trials, scale manufacturing, and prepare for international regulatory engagement.

As CEO Ismail Ceylan shared with Le Figaro, “We are not just developing a molecule—we are building a new therapeutic paradigm. With the right partners, we can bring hope to patients facing resistant cancers.”

We invite investors, collaborators, and healthcare innovators to join us in this mission. Read the full article on Le Figaro Économie here.